These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29269090)

  • 1. Assessment and modelling of antibacterial combination regimens.
    Rao GG; Li J; Garonzik SM; Nation RL; Forrest A
    Clin Microbiol Infect; 2018 Jul; 24(7):689-696. PubMed ID: 29269090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semi-mechanistic pharmacokinetic-pharmacodynamic modelling of antibiotic drug combinations.
    Brill MJE; Kristoffersson AN; Zhao C; Nielsen EI; Friberg LE
    Clin Microbiol Infect; 2018 Jul; 24(7):697-706. PubMed ID: 29229429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.
    Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S88-S94. PubMed ID: 27742639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis.
    Drusano GL; Neely M; Van Guilder M; Schumitzky A; Brown D; Fikes S; Peloquin C; Louie A
    PLoS One; 2014; 9(7):e101311. PubMed ID: 25003557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates].
    Coban AY; Bilgin K; Uzun M; Durupinar B
    Mikrobiyol Bul; 2009 Apr; 43(2):293-7. PubMed ID: 19621615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.
    Brown AN; Drusano GL; Adams JR; Rodriquez JL; Jambunathan K; Baluya DL; Brown DL; Kwara A; Mirsalis JC; Hafner R; Louie A
    mBio; 2015 Nov; 6(6):e01741-15. PubMed ID: 26530386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis.
    Maltempe FG; Caleffi-Ferracioli KR; do Amaral RCR; de Oliveira Demitto F; Siqueira VLD; de Lima Scodro RB; Hirata MH; Pavan FR; Cardoso RF
    Tuberculosis (Edinb); 2017 May; 104():24-29. PubMed ID: 28454646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model.
    Zhuang L; Sy SK; Xia H; Singh RP; Mulder MB; Liu C; Derendorf H
    Int J Antimicrob Agents; 2015 Feb; 45(2):151-60. PubMed ID: 25465523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates.
    Zou L; Liu M; Wang Y; Lu J; Pang Y
    Tuberculosis (Edinb); 2015 Dec; 95(6):839-842. PubMed ID: 26395151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of rifampicin combination therapy for the treatment of enterococcal infections assessed in vivo using a Galleria mellonella infection model.
    Skinner K; Sandoe JAT; Rajendran R; Ramage G; Lang S
    Int J Antimicrob Agents; 2017 Apr; 49(4):507-511. PubMed ID: 28235571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Do different interpretative methods used for evaluation of checkerboard synergy test affect the results?].
    Ozseven AG; Sesli Çetin E; Ozseven L
    Mikrobiyol Bul; 2012 Jul; 46(3):410-20. PubMed ID: 22951653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of linezolid or trimethoprim/sulfamethoxazole in combination with rifampicin as alternative oral treatments based on an in vitro pharmacodynamic model of staphylococcal biofilm.
    El Haj C; Murillo O; Ribera A; Lloberas N; Gómez-Junyent J; Tubau F; Fontova P; Cabellos C; Ariza J
    Int J Antimicrob Agents; 2018 Jun; 51(6):854-861. PubMed ID: 29374577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental design and modelling approach to evaluate efficacy of β-lactam/β-lactamase inhibitor combinations.
    Sy SKB; Derendorf H
    Clin Microbiol Infect; 2018 Jul; 24(7):707-715. PubMed ID: 28760708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatory activity of linezolid and levofloxacin with antituberculosis drugs in Mycobacterium tuberculosis.
    Santos NCS; Scodro RBL; de Almeida AL; Baldin VP; Nakamura de Vasconcelos SS; Siqueira VLD; Caleffi-Ferracioli KR; Campanerut-Sá PAZ; Cardoso RF
    Tuberculosis (Edinb); 2018 Jul; 111():41-44. PubMed ID: 30029913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an
    de Miranda Silva C; Hajihosseini A; Myrick J; Nole J; Louie A; Schmidt S; Drusano GL
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial Peptide Novicidin Synergizes with Rifampin, Ceftriaxone, and Ceftazidime against Antibiotic-Resistant Enterobacteriaceae In Vitro.
    Soren O; Brinch KS; Patel D; Liu Y; Liu A; Coates A; Hu Y
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6233-40. PubMed ID: 26248380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of linezolid alone and combined with other antibiotics against clinical enterococcal isolates.
    Beitdaghar M; Ahmadrajabi R; Karmostaji A; Saffari F
    Wien Med Wochenschr; 2019 Jun; 169(9-10):215-221. PubMed ID: 28924925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity and interactions of levofloxacin, linezolid, ethambutol and amikacin in three-drug combinations against Mycobacterium tuberculosis isolates in a human macrophage model.
    Rey-Jurado E; Tudó G; Soy D; González-Martín J
    Int J Antimicrob Agents; 2013 Dec; 42(6):524-30. PubMed ID: 24080479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
    Zhao W; Zheng M; Wang B; Mu X; Li P; Fu L; Liu S; Guo Z
    Int J Infect Dis; 2016 Nov; 52():23-28. PubMed ID: 27613365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination of silver nanoparticles and visible blue light enhances the antibacterial efficacy of ineffective antibiotics against methicillin-resistant Staphylococcus aureus (MRSA).
    Akram FE; El-Tayeb T; Abou-Aisha K; El-Azizi M
    Ann Clin Microbiol Antimicrob; 2016 Aug; 15(1):48. PubMed ID: 27530257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.